139 related articles for article (PubMed ID: 8695876)
41. Interferon gamma is effective for BM purging in a patient with CML.
Becker M; Fabrega S; Belloc F; Rice A; Barbu V; Reiffers J
Bone Marrow Transplant; 1993 Aug; 12(2):155-8. PubMed ID: 8401363
[TBL] [Abstract][Full Text] [Related]
42. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG
Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049
[TBL] [Abstract][Full Text] [Related]
43. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
44. In vivo purging of peripheral blood stem cells obtained by apheresis, using high-dose chemotherapy and granulocyte colony-stimulating factor in chronic myelogenous leukemia patients.
Borbolla JR; Nájera A; Arana RM; López-Hernández MA; Mendoza Y; Trueba E
J Hematother Stem Cell Res; 2001 Feb; 10(1):19-21. PubMed ID: 11276355
[No Abstract] [Full Text] [Related]
45. Autologous bone marrow transplantation for acute leukemia using ferromagnetic microparticles and monoclonal antibody-purged marrows: demonstration of effectiveness by polymerase chain reaction.
Bieva C; Martiat P; Ferster A; Sariban E; Kedar A; Erdos G; Bron D; Debusscher L; Stryckmans P
Prog Clin Biol Res; 1992; 377():197-204. PubMed ID: 1438416
[No Abstract] [Full Text] [Related]
46. Innovative therapy for chronic myelogenous leukemia.
Miller JS
Hematol Oncol Clin North Am; 1998 Feb; 12(1):173-206. PubMed ID: 9523231
[TBL] [Abstract][Full Text] [Related]
47. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
48. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
49. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
[TBL] [Abstract][Full Text] [Related]
50. Long-term culture and molecular biological studies highlight differences in relative BCR-ABL expression levels in the peripheral blood and bone marrow of a patient with chronic granulocytic leukaemia.
Smith MA; Mills KI; Smith JG
Br J Haematol; 1994 Oct; 88(2):406-8. PubMed ID: 7803292
[TBL] [Abstract][Full Text] [Related]
51. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
[TBL] [Abstract][Full Text] [Related]
52. Prospects for antisense therapy are looking brighter.
Bonn D
Lancet; 1996 Mar; 347(9004):820. PubMed ID: 8622343
[No Abstract] [Full Text] [Related]
53. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
[TBL] [Abstract][Full Text] [Related]
54. Gene therapy for chronic myelogenous leukemia.
Verfaillie CM; McIvor RS; Zhao RC
Mol Med Today; 1999 Aug; 5(8):359-66. PubMed ID: 10431169
[TBL] [Abstract][Full Text] [Related]
55. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
56. Amifostine and 2-CdA: a novel purging strategy in CML autografting?
Korycka A; Robak T
Eur J Haematol; 2000 May; 64(5):347-9. PubMed ID: 10863982
[No Abstract] [Full Text] [Related]
57. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
[TBL] [Abstract][Full Text] [Related]
58. Chronic myeloid leukemia from basics to bedside.
Thijsen S; Schuurhuis G; van Oostveen J; Ossenkoppele G
Leukemia; 1999 Nov; 13(11):1646-74. PubMed ID: 10557038
[TBL] [Abstract][Full Text] [Related]
59. Autologous transplantation for the treatment of chronic myelogenous leukemia.
Bhatia R; Forman SJ
Hematol Oncol Clin North Am; 1998 Feb; 12(1):151-72. PubMed ID: 9523230
[TBL] [Abstract][Full Text] [Related]
60. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
